OncClubAll Oncology NewsPipeline Report
InsightsMedNews WeekMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements and Featured PublicationsAll Publications
CME/CE
Interactive ToolsLearning ModulesPresentationsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • In-person and virtual events just for HCPs
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • CME/CE
    • Biomarker Consortium
    • Subscribe
Advertisement
EHA 2024: Updates in the Treatment of CLL    : Episode 8

Opinion

Video

July 22, 2024

Navigating Treatment Approaches for R/R CLL

Author(s):

Catherine C. Coombs, MD
Matthew S. Davids, MD, MMSc
Catherine C. Coombs, MD
Matthew S. Davids, MD, MMSc
Richardo D. Parrondo, MD
Nicole Lamanna, MD
Alexey V. Danilov, MD, PhD

A clinician outlines their treatment strategy for relapsed/refractory chronic lymphocytic leukemia patients, emphasizing how previous treatment history influences subsequent therapy choices.

EP: 1.Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024

EP: 2.Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL

EP: 3.Frontline BTKi Selection

EP: 4.Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib

EP: 5.Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy

EP: 6.Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL

EP: 7.EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches

Now Viewing

EP: 8.Navigating Treatment Approaches for R/R CLL

EP: 9.How Experts View MAIC Data That was Presented at EHA 2024

EP: 10.BTKi Intolerance in Real-world Practice & Management Strategy

EP: 11.Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities

EP: 12.Approach to Hypertension Management With BTKi Treatment

EP: 13.Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib

EP: 14.Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing

EP: 15.Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice

EP: 16.TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices

EP: 17.EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL

EP: 18.Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673

EP: 19.Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL

EP: 20.Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies

  1. What is your general treatment approach in patients with R/R CLL?
    • How does prior 1L therapy influence your treatment decision?
    • In what clinical scenarios may you consider a non-covalent BTKi for patients with R/R CLL?
Related Videos
John Seymour, MBBS, FRACP, PhD
3 KOLs are featured in this series.
3 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
1 KOL is featured in this series.
Related Content
Advertisement
William G. Wierda, MD, PhD
September 6th 2024

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Consuelo Bertossi, MD, assistant doctor, Division of CLL, Department of Internal Medicine III, Ulm University Hospital
August 29th 2024

TP53 Mutations Have Strong Prognostic Value for PFS and OS Outcomes in CLL

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Matthew S. Davids, MD, MMSc
August 16th 2024

Acalabrutinib With/Without Obinutuzumab Is Effective in Higher-Risk Chronic Lymphocytic Leukemia

Stephen Opat, of Monash Health
August 12th 2024

Sonrotoclax/Zanubrutinib Leads to Durable Responses in R/R CLL/SLL

Related Content
Advertisement
William G. Wierda, MD, PhD
September 6th 2024

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Consuelo Bertossi, MD, assistant doctor, Division of CLL, Department of Internal Medicine III, Ulm University Hospital
August 29th 2024

TP53 Mutations Have Strong Prognostic Value for PFS and OS Outcomes in CLL

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Matthew S. Davids, MD, MMSc
August 16th 2024

Acalabrutinib With/Without Obinutuzumab Is Effective in Higher-Risk Chronic Lymphocytic Leukemia

Stephen Opat, of Monash Health
August 12th 2024

Sonrotoclax/Zanubrutinib Leads to Durable Responses in R/R CLL/SLL

Latest Conference Coverage

Subcutaneous Rituximab Remains Underutilized in Non-Hodgkin Lymphoma

Dr Seymour on the Role of Mutational Profiling in CLL

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777
© 2024 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact